Hidekazu Tokuhara

ORCID: 0000-0001-8619-603X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • X-ray Diffraction in Crystallography
  • Crystallization and Solubility Studies
  • Crystallography and molecular interactions
  • Psoriasis: Treatment and Pathogenesis
  • Malaria Research and Control
  • Magnetic Properties of Alloys
  • Synthesis and Catalytic Reactions
  • Renin-Angiotensin System Studies
  • Receptor Mechanisms and Signaling
  • Rare-earth and actinide compounds
  • NF-κB Signaling Pathways
  • Free Radicals and Antioxidants
  • Marine Toxins and Detection Methods
  • Neurotransmitter Receptor Influence on Behavior
  • Biochemical and Molecular Research
  • Oxidative Organic Chemistry Reactions
  • Computational Drug Discovery Methods
  • Pharmacological Receptor Mechanisms and Effects
  • Metallurgical and Alloy Processes
  • Mosquito-borne diseases and control
  • Chemical Reactions and Mechanisms
  • Synthesis and Biological Evaluation
  • Magnetic Properties and Applications
  • Porphyrin and Phthalocyanine Chemistry
  • Cytokine Signaling Pathways and Interactions

Takeda (Japan)
2016-2021

Osaka University
2002-2011

Heriot-Watt University
2003

Okayama University
1986-2002

A series of tetrahydronaphthyridine derivatives as novel RORγt inverse agonists were designed and synthesized. We reduced the lipophilicity tetrahydroisoquinoline compound 1 by replacement trimethylsilyl group SBDD-guided scaffold exchange, which successfully afforded 7 with a lower log D value tolerable in vitro activity. Consideration LLE values subsequent optimization carboxylate tether led to discovery [ cis-3-({(5 R)-5-[(7-fluoro-1,1-dimethyl-2,3-dihydro-1...

10.1021/acs.jmedchem.8b00061 article EN Journal of Medicinal Chemistry 2018-03-06

The therapeutic potential of monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases has attracted attention worldwide. However, the availability reversible-type inhibitor is still limited to clarify pharmacological effect. Herein, we report discovery novel spiro chemical series as potent and reversible MAGL with a different binding mode using Arg57 His121. Starting from hit compound 1 its co-crystal structure MAGL, structure-based drug (SBDD) approach enabled us...

10.1021/acs.jmedchem.1c00432 article EN cc-by-nc-nd Journal of Medicinal Chemistry 2021-07-30

Of several bis(alkyldioxy)alkanes and the related acyclic peroxides prepared in this study, 1,1-bis(methyldioxy)cyclododecane showed most notable antimalarial activity particularly vivo (almost a half of that artemisinin).

10.1021/jm010473w article EN Journal of Medicinal Chemistry 2002-02-13

Structural and magnetic studies have been carried out on a bcc phase that appears in melt-spun rare earth-iron based alloys during heat treatment at temperatures ranging from 700K to 770K. It has found the lattice constant very close for α-Fe it is soft magnet with Curie 400-450K range. Relation of this boundary sintered Nd-Fe-B its role hardening mechanism magnets discussed.

10.1109/tmag.1986.1064430 article EN IEEE Transactions on Magnetics 1986-09-01

The aspartic proteinase renin is an attractive target for the treatment of hypertension and cardiovascular/renal disease such as chronic kidney heart failure. We introduced S1′ site binder into lead compound 1 guided by structure-based drug design (SBDD), further optimization physicochemical properties led to discovery benzimidazole derivative 10 (1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-yl)carbonylpiperidin-3-yl]-1H-benzimidazole-2-carboxamide hydrochloride, TAK-272)...

10.1021/acsmedchemlett.6b00251 article EN publisher-specific-oa ACS Medicinal Chemistry Letters 2016-09-12

Ozonolysis of (alkenyldioxy)cyclododecyl hydroperoxides in trifluoroethanol gave a separable mixture the corresponding alpha-hydroperoxy- and alpha-hydroxy-substituted spiro-tetraoxacycloalkanes with ring sizes range 7-12. Dehydration or oxidation hydroxy-compounds afforded peroxylactones. The solid-state structure 1,2,6,7-tetraoxaspiro[7.11]nonadecan-3-one was determined by X-ray crystallographic analysis.

10.1039/b300342f article EN Organic & Biomolecular Chemistry 2003-03-27

Abstract For see ChemInform in Full Text.

10.1002/chin.200336137 article EN ChemInform 2003-08-12
Coming Soon ...